Outcome of salvage intra-arterial chemotherapy for recurrent retinoblastoma.

ABSTRACT:

Purpose

To examine the outcome of salvage intra-arterial chemotherapy (IAC) for patients with recurrent retinoblastoma after the initial course of IAC and determine the factors influencing clinical outcome.

Methods

A total of 73 eyes of 71 patients with recurrent retinoblastoma undergoing salvage IAC after initial successfully IAC between May 2014 and May 2019 were retrospectively reviewed for clinical outcomes. Ocular survival and progression-free survival were used to examine the efficacy of salvage IAC. The factors influencing clinical outcomes were determined using univariate and multivariate analyses.

Results

The salvage IAC was delivered at mean 9.4 months (median 7, range 2.1-38.3 months) following the last cycle of initial IAC. 86.5% (64/73) eyes relapsed 16 m

SUBMITTER: Li J 

PROVIDER: S-EPMC9581931 | biostudies-literature | 2022 Nov

REPOSITORIES: biostudies-literature